Search filters

List of works by Naiyer A Rizvi

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

scientific article published on 22 December 2020

A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development

scientific article

Classification of current anticancer immunotherapies

scientific article

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

scientific article published in February 2006

Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis

scientific article published on January 2010

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

scientific article

Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene

scientific article published on 10 May 2011

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

scientific article published on 12 October 2017

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

scientific article (publication date: 22 October 2015)

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

scientific article

Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients With Advanced Solid Tumors

scientific article published on 14 August 2020

Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

scientific article published on 04 September 2020

Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response

scientific article published on 30 October 2020

Paulina is supported by:

About Paulina

Help